Greg Cosma

Greg Cosma is a seasoned expert in the biopharmaceutical industry with over 25 years of experience. Currently serving on the Scientific Advisory Boards of LTZ Therapeutics, Aarvik Therapeutics Inc, Immune-Onc Therapeutics, and Erasca, Inc., as well as leading their own consulting firm, Cosma Biopharma Consulting LLC, Greg specializes in guiding companies through successful drug development strategies. Previous roles include Vice President of Research and Early Development at Genentech, where responsibilities encompassed heading the Safety Assessment organization and chairing the Development Review Committee, as well as executive positions at Bristol-Myers Squibb and Pfizer Pharmaceuticals. Greg's academic background includes a PhD in Pharmacology and Toxicology from The University of Kansas and a Bachelor of Science in Biochemistry from the University of Illinois Urbana-Champaign, complemented by post-doctoral training at NYU Grossman School of Medicine.